ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GNBT Generex Biotechnology Corporation (CE)

0.0006
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Generex Biotechnology Corporation (CE) USOTC:GNBT OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0006 0.00 01:00:00

Initial Statement of Beneficial Ownership (3)

11/09/2019 8:46pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Prioletti Mark Joseph SE

2. Date of Event Requiring Statement (MM/DD/YYYY)
6/27/2019 

3. Issuer Name and Ticker or Trading Symbol

GENEREX BIOTECHNOLOGY CORP [GNBT]

(Last)        (First)        (Middle)

1121 PALMER COURT

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)

(Street)

CRYSTAL LAKE, IL 60014      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)

 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Voting Shares 3568 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Prioletti Mark Joseph SE
1121 PALMER COURT
CRYSTAL LAKE, IL 60014
X



Signatures
/s/ Mark Prioletti6/27/2019
**Signature of Reporting PersonDate

1 Year Generex Biotechnology (CE) Chart

1 Year Generex Biotechnology (CE) Chart

1 Month Generex Biotechnology (CE) Chart

1 Month Generex Biotechnology (CE) Chart

Your Recent History

Delayed Upgrade Clock